TY - BOOK ID - 8656750 TI - Biopatent law : patent strategies and patent management AU - Hubel, Andreas. AU - Schmelcher, Thilo. AU - Storz, Ulrich. PY - 2012 SN - 3642248454 3642248462 9786613573179 1280395257 9781280395253 9783642248467 PB - New York : Springer, DB - UniCat KW - Biotechnology -- Law and legislation. KW - Biotechnology -- Patents. KW - Biotechnology. KW - Biotechnology KW - Biology KW - Law, Politics & Government KW - Health & Biological Sciences KW - Cytology KW - Law, General & Comparative KW - Law and legislation KW - Law and legislation. KW - Life sciences. KW - Pharmaceutical technology. KW - Biochemistry. KW - Cell biology. KW - Microbiology. KW - Commercial law. KW - Life Sciences. KW - Cell Biology. KW - Pharmaceutical Sciences/Technology. KW - Biochemistry, general. KW - Commercial Law. KW - Biopiracy KW - Cytology. KW - Chemical engineering KW - Genetic engineering KW - Business KW - Business law KW - Commerce KW - Law, Commercial KW - Mercantile law KW - Law KW - Law merchant KW - Maritime law KW - Biological chemistry KW - Chemical composition of organisms KW - Organisms KW - Physiological chemistry KW - Chemistry KW - Medical sciences KW - Pharmaceutical laboratory techniques KW - Pharmaceutical laboratory technology KW - Technology, Pharmaceutical KW - Technology KW - Cell biology KW - Cellular biology KW - Cells KW - Cytologists KW - Microbial biology KW - Microorganisms KW - Composition UR - https://www.unicat.be/uniCat?func=search&query=sysid:8656750 AB - Patents protecting biotechnological invention become ever more important. Because biotechnology has many differences with respect to other technologies, lessons learned in other fields of technology cannot simply be transferred to adopt a suitable strategy for dealing with biotechnology inventions. In this volume, general aspects of biopatent law will be discussed. This involves questions of patentability, including ethical issues and issues of technicality, as well as questions of patent exhaustion in cases were reproducible subject matter, like cells or seeds, is protected. Moreover, active and passive patent strategies are addressed. Further, insight will be given into patent lifetime management and additional protective measures, like supplementary protection certificates and data exclusivity. Here, strategies are discussed how market exclusivity can be extended as long as possible, which is particularly important for biopharmaceutical drugs, which create high R&D costs. ER -